Left Ventricular Hypertrophy and Antiarrhythmic Drugs in Atrial Fibrillation: Impact on Mortality

@article{Chung2014LeftVH,
  title={Left Ventricular Hypertrophy and Antiarrhythmic Drugs in Atrial Fibrillation: Impact on Mortality},
  author={Roy Chung and P. Houghtaling and Michael J. Tchou and M. Niebauer and B. Lindsay and P. Tchou and M. Chung},
  journal={Pacing and Clinical Electrophysiology},
  year={2014},
  volume={37}
}
BACKGROUND Despite sparse clinical data, current atrial fibrillation (AF) guidelines favor amiodarone as a drug of choice for patients with left ventricular hypertrophy (LVH. [...] Key MethodMETHODS In an observational cohort analysis of patients who underwent cardioversion for AF, patients with LVH, defined as left ventricular wall thickness ≥1.4 cm, by echocardiogram prior to their first cardioversion, were included; clinical data, including antiarrhythmic drugs and ejection fraction (LVEF), were…Expand
Guidelines for Potassium Channel Blocker Use.
  • A. Gillis
  • Medicine
  • Cardiac electrophysiology clinics
  • 2016
Rhythm control in atrial fibrillation
Use of Flecainide for the Treatment of Atrial Fibrillation.
Dysrhythmias and Hypertension
REASONS FOR UNJUSTIFIED ADMINISTRATION OF AMIODARONE IN CORONARY CARE UNIT
Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society
  • G. Dan, A. Martı́nez-Rubio, +17 authors C. Wolpert
  • Medicine
  • Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
  • 2018
...
1
2
...

References

SHOWING 1-10 OF 37 REFERENCES
Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target.
Safety considerations in the pharmacological management of atrial fibrillation.
  • A. Camm
  • Medicine
  • International journal of cardiology
  • 2008
Arrhythmogenic mechanisms in left ventricular hypertrophy.
  • R. Wołk
  • Medicine
  • Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
  • 2000
...
1
2
3
4
...